Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Therapeutic efficacy of artemether–lumefantrine in North-Eastern states of India and prevalence of drug resistance-associated molecular markers

View through CrossRef
Abstract Background Plasmodium falciparum is the main cause of malaria in North-Eastern (NE) states of India. Artemether–lumefantrine (AL) was introduced as first-line therapy against uncomplicated P. falciparum cases in 2013 after the emergence of resistance to sulfadoxine–pyrimethamine. The aim of the study was to assess the therapeutic efficacy of AL and status of molecular markers in the circulating parasites. Methods Therapeutic efficacy of AL was assessed in NE states as per World Health Organization guidelines. Patients with P. falciparum positive peripheral blood smear were enrolled and treated with AL and clinical and parasitological parameters were monitored over a 28-day follow-up period. Furthermore, the pfmdr1, pfdhfr, pfdhps and pfk13 genes were amplified and sequenced for mutation analysis. Results A total of 231 cases were enrolled and therapeutic efficacy was determined in 215 (93.1%) patients who completed their 28 days’ follow-up while 10 patients withdrew and 6 were lost to follow up during study. Overall 99.5% and 98.6% of adequate clinical and parasitological response was observed with and without PCR correction, respectively. Only three cases (1.4%) of late parasitological failure were observed in Mizoram site. One case of recrudescence and two cases of reinfection were detected by msp1 and msp2 genotyping. Mutation analysis showed the 15.8%, 100%, 90.5% mutants in pfmdr1, pfdhfr and pfdhps gene respectively and three non-synonymous mutations were also found in pfk13gene. Conclusions This study reports that AL is efficacious against uncomplicated P. falciparum cases in NE states of India. However, prevalence of mutations in molecular marker associated with anti-malarial resistance (pfmdr1, pfdhfr, pfdhps and pfk13) gene indicate possible emergence of drug resistance. This is to underline the fact that the drug is efficacious for now, but rising mutations indicate that continuous monitoring is essential for effective treatment regime.
Title: Therapeutic efficacy of artemether–lumefantrine in North-Eastern states of India and prevalence of drug resistance-associated molecular markers
Description:
Abstract Background Plasmodium falciparum is the main cause of malaria in North-Eastern (NE) states of India.
Artemether–lumefantrine (AL) was introduced as first-line therapy against uncomplicated P.
falciparum cases in 2013 after the emergence of resistance to sulfadoxine–pyrimethamine.
The aim of the study was to assess the therapeutic efficacy of AL and status of molecular markers in the circulating parasites.
Methods Therapeutic efficacy of AL was assessed in NE states as per World Health Organization guidelines.
Patients with P.
falciparum positive peripheral blood smear were enrolled and treated with AL and clinical and parasitological parameters were monitored over a 28-day follow-up period.
Furthermore, the pfmdr1, pfdhfr, pfdhps and pfk13 genes were amplified and sequenced for mutation analysis.
Results A total of 231 cases were enrolled and therapeutic efficacy was determined in 215 (93.
1%) patients who completed their 28 days’ follow-up while 10 patients withdrew and 6 were lost to follow up during study.
Overall 99.
5% and 98.
6% of adequate clinical and parasitological response was observed with and without PCR correction, respectively.
Only three cases (1.
4%) of late parasitological failure were observed in Mizoram site.
One case of recrudescence and two cases of reinfection were detected by msp1 and msp2 genotyping.
Mutation analysis showed the 15.
8%, 100%, 90.
5% mutants in pfmdr1, pfdhfr and pfdhps gene respectively and three non-synonymous mutations were also found in pfk13gene.
Conclusions This study reports that AL is efficacious against uncomplicated P.
falciparum cases in NE states of India.
However, prevalence of mutations in molecular marker associated with anti-malarial resistance (pfmdr1, pfdhfr, pfdhps and pfk13) gene indicate possible emergence of drug resistance.
This is to underline the fact that the drug is efficacious for now, but rising mutations indicate that continuous monitoring is essential for effective treatment regime.

Related Results

In vitro study of the interaction between artemether-lumefantrine and ciprofloxacin/metronidazole
In vitro study of the interaction between artemether-lumefantrine and ciprofloxacin/metronidazole
This study investigated the in vitro interactions between artemether-lumefantrine and ciprofloxacin or metronidazole in their co-administration. Commercial brands of artemether-lum...
Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration
Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration
Background: Artemether and lumefantrine display low aqueous solubility leading to poor release profile; hence the need for the use of lipid-based systems to improve their oral bioa...
Selection of pfcrt K76 and pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in Mali
Selection of pfcrt K76 and pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in Mali
Background: Artemether-lumefantrine is a highly effective artemisinin-based combination therapy that was adopted in Mali as first-line treatment for uncomplicated Plasmodium falcip...
Prevalence of substandard quality artemether-lumefantrine antimalarial agents in Uganda
Prevalence of substandard quality artemether-lumefantrine antimalarial agents in Uganda
Abstract Background: Substandard antimalarial agents are a key challenge to effective malaria control and elimination efforts especially in sub-Saharan Africa. The quality ...
Current Perspectives on Cystic Echinococcosis: A Systematic Review
Current Perspectives on Cystic Echinococcosis: A Systematic Review
Abstract Introduction: Hydatidosis, a zoonotic disease caused by the larval stage of Echinococcus granulosus, is a significant public health concern with notable economic impact. I...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract Introduction Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...

Back to Top